Genetic Analysis of Prostate Cancer to Identify Predictive Markers of Disease Relapse or Metastatic Evolution (CHRU-WCMC)

University Hospital, Lille

Status: Unknown

Conditions: Prostatic Neoplasms

Study type: Observational

Funder types: Other

Identifiers

NCT03421015

2017_12

2017-A01870-53 (Other Identifier)

Details and patient eligibility

About

Developing a genetic study on localized or locally advanced prostate cancer. The aim of the study is to identify genomic alteration predictive of metastatic recurrence in the context of primary heterogeneity, by using the next generation sequencing (NGS) techniques.

Identifying such biomarkers may be useful to detect a higher relapse risk, and thus lower the mortality rate.

Enrollment: 84 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients managed by radical prostatectomy for prostate cancer between 2000 and 2016.
• Follow up > 6 years
• Negative pre surgical extension assessment
• Prognostic Grade Groups (OGG) III-IV-V
• Biochemical recurrence defined by 2 consecutive PSA rises ≥ 0,2 ng/mL
• Metastasis positive imaging

Exclusion criteria

• Neoadjuvant therapy
• Follow up < 6 years
• Prognostic Grade Groups (PGG) I-II
• Biochemical recurrence with metastasis negative imaging

Trial design

84 participants in 2 patient groups

case group

Description:

patients with biochemical recurrence and positive imaging (case group)

Control Group

Description:

patients without biochemical recurrence (control group)